Cristian Suarez-Cabrera
Overview
Explore the profile of Cristian Suarez-Cabrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Canizo C, Guerrero-Ramos F, Perez Escavy M, Lodewijk I, Suarez-Cabrera C, Morales L, et al.
Oncoimmunology
. 2024 Dec;
14(1):2438291.
PMID: 39698899
High-risk non-muscle-invasive bladder cancer (NMIBC) presents high recurrence and progression rates. Despite the use of Bacillus Calmette-Guérin gold-standard immunotherapy and the recent irruption of anti-PD-1/PD-L1 drugs, we are missing a...
2.
Nunes S, Morales L, Rubio C, Munera-Maravilla E, Lodewijk I, Suarez-Cabrera C, et al.
Cell Death Discov
. 2024 Jan;
10(1):1.
PMID: 38172127
Alterations in the epigenetic machinery in both tumor and immune cells contribute to bladder cancer (BC) development, constituting a promising target as an alternative therapeutic option. Here, we have explored...
3.
Hervas-Salcedo R, Fernandez-Garcia M, Hernando-Rodriguez M, Suarez-Cabrera C, Bueren J, Yanez R
Front Immunol
. 2023 Feb;
14:1062086.
PMID: 36817457
Previous clinical trials have shown that mesenchymal stromal cells (MSCs) can modulate graft versus host disease (GvHD) after allogeneic hematopoietic transplantation, although with variable efficacy. To improve the anti-GvHD effect...
4.
Suarez-Cabrera C, Estudillo L, Ramon-Gil E, Martinez-Fernandez M, Peral J, Rubio C, et al.
Eur Urol
. 2022 Sep;
82(6):663-667.
PMID: 36085102
No abstract available.
5.
Durendez-Saez E, Calabuig-Farinas S, Torres-Martinez S, Moreno-Manuel A, Herreros-Pomares A, Escorihuela E, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804987
Lung cancer is a malignant disease with high mortality and poor prognosis, frequently diagnosed at advanced stages. Nowadays, immense progress in treatment has been achieved. However, the present scenario continues...
6.
Bernardini A, Duenas M, Martin-Soberon M, Rubio C, Suarez-Cabrera C, Ruiz-Palomares R, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053540
Background And Aims: Metastatic urothelial carcinoma (mUC) remains an incurable disease with limited treatment options after platinum-based chemotherapy and immune checkpoint blockade (ICB). Vinflunine has shown a modest increase in...
7.
Rubio C, Avendano-Ortiz J, Ruiz-Palomares R, Karaivanova V, Alberquilla O, Sanchez-Dominguez R, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053451
Bladder cancer (BC) is the second most frequent cancer of the genitourinary system. The most successful therapy since the 1970s has consisted of intravesical instillations of (BCG) in which the...
8.
Suarez-Cabrera C, Ojeda-Perez I, Sanchez-Baltasar R, Page A, Bravo A, Navarro M, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771750
is a relatively uncharacterized gene of the Ras superfamily. It is expressed in ES cells and in the first stages of embryonic development; later on, it is silenced in the...
9.
Carvalho S, Abreu C, Ferreira D, Lima L, Ferreira J, Santos L, et al.
Front Oncol
. 2020 Oct;
10:1774.
PMID: 33042825
Bladder cancer is the most common malignancy of the urinary tract, having one of the highest recurrence rates and progression from non-muscle to muscle invasive bladder cancer that commonly leads...
10.
Hermanova I, Zuniga-Garcia P, Caro-Maldonado A, Fernandez-Ruiz S, Salvador F, Martin-Martin N, et al.
J Exp Med
. 2020 Mar;
217(6).
PMID: 32219437
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model...